NVAX

Novavax

--(--)

Market Open: --

--(--)

Post-Market: --

Signals Analysis

Buy signal 0

Sell signal 2

EPS Below Expectations

Revenue Below Expectations

Key Stats

--DAY`S RANGE--

--52 WK RANGE--

Open

Prev.Close

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

Low

52 Week High

52 Week Low

About NVAX

Novavax, Inc.

A world's leading COVID-19 vaccine development company

Industry

Biological Technology

Established Date

Invalid Date

Listing Date

07/01/2001

Exchange

NASDAQ Stock Exchange

Full-time Employees

952

Fiscal Year Ends

12-31

Website

www.novavax.com

Security Type

Common stock

Office address

700 Quince Orchard Road, Gaithersburg, Maryland 20878

Business

Introduction

Novavax, Inc., incorporated in 1987 under the laws of the State of Delaware, is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The company's vaccine technology platform is based on proprietary recombinant nanoparticle vaccine technology including virus-like particles (VLP) and protein nanoparticle vaccine candidates. The company's vaccine candidates are genetically engineered three-dimensional nanostructures that contain immunologically important proteins. The company's vaccine product pipeline targets a variety of infectious diseases, and drug candidates are currently in clinical development for respiratory syncytial virus (RSV), seasonal influenza, and pandemic influenza. In addition, the company's joint venture in India, CPL Biologics Private Limited (CPLB), is actively developing a number of vaccine candidates that have been genetically engineered by Novavax.

Company Financials

EPS

NVAX has released its 2024 Q4 earnings. EPS was reported at -0.51, versus the expected -0.51, meeting expectations. The chart below visualizes how NVAX has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

NVAX has released its 2024 Q4 earnings report, with revenue of 88.31M, reflecting a YoY change of -69.69%, and net profit of -81.03M, showing a YoY change of 54.58%. The Sankey diagram below clearly presents NVAX’s revenue sources and cost distribution.